Next Article in Journal
Chinese Medicine and Biomodulation in Cancer Patients—Part One
Previous Article in Journal
Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 15
Issue 1
10.3747/co.2008.200
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Health Management Program: Factors Influencing Completion of Therapy with High-Dose Interferon Alfa-2b for High-Risk Melanoma

by
N. Levesque
1,
K. Mitchinson
2,
D. Lawrie
3,
L. Fedorak
4,
D. MacDonald
5,
C. Normand
6 and
J.F. Pouliot
7,8,*
1
Hamilton Regional Cancer Centre, Hamilton, ON, Canada
2
Royal Victoria Hospital, Barrie, ON, Canada
3
Sunnybrook Regional Cancer Centre, Toronto, ON, Canada
4
Cross Cancer Institute, Edmonton, AB, Canada
5
Mississauga, ON, Canada
6
Centre Hospitalier des Vallées de l’Outaouais, Gatineau, QC, Canada
7
Schering-Plough Canada, Pointe-Claire, QC, Canada
8
16750 Autoroute Transcanadienne, Kirkland, Quebec H9H 4M7, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2008, 15(1), 36-41; https://doi.org/10.3747/co.2008.200
Submission received: 12 October 2007 / Revised: 14 November 2007 / Accepted: 9 December 2007 / Published: 1 January 2008
Versions Notes

Abstract

The goal of the 1-year observational, multicentre, open-label study reported here was to identify factors influencing adherence to high-dose interferon alfa-2b adjuvant therapy in patients at high risk of recurrence following surgical excision of malignant melanoma. The study was carried out in 23 tertiary-care centres across Canada.
Keywords: melanoma; interferon alfa-2b; clinical trial; adherence melanoma; interferon alfa-2b; clinical trial; adherence

Share and Cite

MDPI and ACS Style

Levesque, N.; Mitchinson, K.; Lawrie, D.; Fedorak, L.; MacDonald, D.; Normand, C.; Pouliot, J.F. Health Management Program: Factors Influencing Completion of Therapy with High-Dose Interferon Alfa-2b for High-Risk Melanoma. Curr. Oncol. 2008, 15, 36-41. https://doi.org/10.3747/co.2008.200

AMA Style

Levesque N, Mitchinson K, Lawrie D, Fedorak L, MacDonald D, Normand C, Pouliot JF. Health Management Program: Factors Influencing Completion of Therapy with High-Dose Interferon Alfa-2b for High-Risk Melanoma. Current Oncology. 2008; 15(1):36-41. https://doi.org/10.3747/co.2008.200

Chicago/Turabian Style

Levesque, N., K. Mitchinson, D. Lawrie, L. Fedorak, D. MacDonald, C. Normand, and J.F. Pouliot. 2008. "Health Management Program: Factors Influencing Completion of Therapy with High-Dose Interferon Alfa-2b for High-Risk Melanoma" Current Oncology 15, no. 1: 36-41. https://doi.org/10.3747/co.2008.200

APA Style

Levesque, N., Mitchinson, K., Lawrie, D., Fedorak, L., MacDonald, D., Normand, C., & Pouliot, J. F. (2008). Health Management Program: Factors Influencing Completion of Therapy with High-Dose Interferon Alfa-2b for High-Risk Melanoma. Current Oncology, 15(1), 36-41. https://doi.org/10.3747/co.2008.200

Article Metrics

Back to TopTop